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Abstract
Background: The receptor tyrosine kinase family includes many transmembrane proteins with diverse physiological
and pathophysiological functions. The involvement of tyrosine kinase signaling in promoting a more aggressive
tumor phenotype within the context of chemotherapeutic evasion is gaining recognition. The Ron receptor is a
tyrosine kinase receptor that has been implicated in the progression of breast cancer and evasion of tamoxifen
therapy.
Results: Here, we report that Ron expression is correlated with in situ, estrogen receptor alpha (ERa)-positive
tumors, and is higher in breast tumors following neoadjuvant tamoxifen therapy. We also demonstrate that the
majority of mammary tumors isolated from transgenic mice with mammary specific-Ron overexpression (MMTV-
Ron mice), exhibit appreciable ER expression. Moreover, genetic-ablation of ERa, in the context of Ron
overexpression, leads to delayed mammary tumor initiation and growth, but also results in an increased metastasis.
Conclusions: Ron receptor overexpression is associated with ERa-positive human and murine breast tumors. In
addition, loss of ERa on a Ron overexpressing background in mice leads to the development of breast tumors
which grow slower but which exhibit more metastasis and suggests that targeting of ERa, as in the case of
tamoxifen therapy, may reduce the growth of Ron overexpressing breast cancers but may cause these tumors to
be more metastatic.
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Background
To date, the most successful pharmacological therapies
specifically targeting breast cancer include anti-estrogens
and receptor tyrosine kinase (RTK) modulating drugs
[1]. Accordingly, there have been numerous studies
examining signaling paradigms between estrogen and
RTK signaling pathways [2-4] which have provided evi-
dence that RTKs are able to activate estrogen receptor
alpha (ERa) in breast cancers independent of its ligand
estrogen. This activation of ERa by RTKs leads to an
ERa transcriptional program that enhances cell survival.
The dependency of this activation on the RTK ligand is
still an area of active investigation. More importantly,
however, this signaling crosstalk between RTKs and
ERa may predict resistance to anti-estrogen hormonal
therapies, including tamoxifen [2,5]. Specifically, studies
have shown that activation of EGFR, Her2, cMet, IGFR,
RET and recently, Ron RTK, lead to phosphorylation
and activation of ERa which enhances survival of breast
cancer in the presence of anti-estrogen therapy [4,6-8].
Ron is a cell surface RTK related to the c-Met recep-
tor that has been identified as an oncogene in the devel-
opment and growth of human epithelial tumors [9]. In
the developing mammary gland, Ron is expressed during
the pubertal growth stages, and then again during preg-
nancy and lactation, and its expression remains low in
quiescent glands [10]. In normal mammary develop-
ment, genetic loss of Ron signaling has been shown to
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alter mammary gland branching morphogenesis during
puberty [10]. In cell lines, wild-type Ron overexpression
is associated with induction of oncogenic properties,
including malignant transformation, proliferation, and
migration [11]. Overexpression of Ron in transgenic
mouse models of both lung and breast cancer is asso-
ciated with tumorigenesis in both organs [12,13]; while
deletion of Ron in transgenic mice expressing polyoma
virus middle T antigen caused a significant reduction in
breast tumor formation and growth [14]. Additionally,
Ron is known to be upregulated in a number of human
epithelial cancers, including breast, lung, stomach,
colon, pancreas, and prostate. Specifically, Ron is highly
expressed in approximately 50% of human breast can-
cers [15]. Given the important role of Ron in human
and mouse tumorigenesis, identifying the functions and
signaling pathways associated with this RTK may pro-
vide essential clues to combat disease progression.
Recent data has shown that Ron activation leads to
the phosphorylation and activation ERa. In this case,
exogenous overexpression of Ron or ligand activation of
endogenous Ron led to enhanced survival of several
ERa-positive breast cancer cell lines in the presence of
the anti-estrogen therapy tamoxifen [4]. Estrogen recep-
tor alpha and its ligand estrogen are important regula-
tors of mammary gland development and breast
carcinogenesis. During development ERa is critical for
peripubertal ductal elongation, and is a permissive factor
in alveolar expansion during pregnancy [16-19]. In can-
cer, ERa transcriptional programming provides survival
and growth stimulation that is advantageous for tumors
and the majority of human breast cancers express ERa.
Consequently, ERa is the target of a family of anti-estro-
gen pharmacological compounds including tamoxifen.
Although tamoxifen treatment is often initially success-
ful at preventing the proliferative effect of estrogen on
ERa, the preponderance of patients develop tamoxifen-
resistance [5] and the recurrent tumors tend to be more
aggressive [17]. Tamoxifen resistance has become a
major obstacle to effective treatment of ERa-positive
breast cancer.
Complementing previously published work, we show
here that Ron is overexpressed and correlated with early
stage ERa-positive breast cancers. To directly demon-
strate the effect of ERa inactivation has on breast can-
cer, in the presence of Ron, we have created ERa
-replete and ERa -conditionally deficient animals on a
Ron overexpressing background. We show for the first
time that mammary-specific ERa deletion increases
breast tumor latency, but also leads to a more metastatic
phenotype. Interestingly, these studies suggest a negative
consequence of anti-estrogen therapy in Ron expressing
tumors on the promotion of metastasis.
Results
Correlations between MST1R/Ron, ER & Breast Cancer
Staging
Previous studies have shown that Ron activation leads to
phosphorylation and activation of ER [4]. However, no
studies have shown an association between Ron and ER in
the human patient population. To accomplish this we first
mined publically available data in Oncomine. Two inde-
pendent microarray studies demonstrated that Ron
(MST1R) expression positively correlates with ER-positive
breast cancers (Figure 1A) [20,21]. Furthermore, Ron
expression is also increased in patients following neoadju-
vant tamoxifen therapy (Figure 1B).
Figure 1 MST1R (Ron) mRNA expression in publically available
data sets. (A) Comparison of MST1R expression in human breast tumor
tissue between estrogen receptor positive and estrogen receptor
negative tumors. Shown are box and whisker plots from two
independent data sets; line represents the median, box represents
interquartile range and whiskers represent min/max (p < 0.01 for each
comparison utilizing the Mann-Whitney test). (B) Utilizing the Sotiriou et
al. data set, we show MST1R expression in breast cancer tissue between
patients who received neoadjuvant tamoxifen (Yes) versus those who
did not receive neoadjuvant therapy (No) (p < 0.01, Mann-Whitney test).
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Ron receptor overexpression has been reported in
approximately half of breast cancers [15,22]. However,
little information is known regarding the association of
Ron overexpression with a particular subtype or stage of
human cancer. To address this, immunohistochemistry
for Ron was performed on three independent breast
cancer tissue arrays. The arrays contained 250 human
breast tumor specimens. Ron staining and expression
were determined as previously described [22,23]. As
depicted in Figure 2A, Ron was found to be more highly
expressed in carcinomas in situ versus invasive carcino-
mas. In an analysis of Ron expression by T-stage, Figure
2B demonstrates that Ron is inversely associated with
T-stage with Ron expression being highest in the in situ
tumors (Tis), especially when compared to T2 and T3/4.
T3 and T4 were grouped together due to the small
number of T4 tumors present on the array. Tis versus
T1, and T2 versus T3/4 did not reach statistical signifi-
cance, but all other pairwise comparisons had p-values
< 0.05. Altogether, the data suggests Ron is prominently
featured in early stage ER+ tumors.
Tumor Characterization in WAP-Cre/ERfl/fl/MMTV-Ron Mice
Since Ron is associated with early stage ER+ tumors, a
set of genetic experiments was performed to test the
hypothesis that tumor progression is altered in mice
where ERa is non-functional and Ron is overexpressed.
To accomplish this, the MMTV-Ron driven mouse
model of breast cancer was utilized. As previously
reported, MMTV-Ron mice develop breast cancer with
100% penetrance [13]. To generate ERfl/fl/MMTV-Ron
mice (ERRN), MMTV-Ron mice were crossed to ERfl/fl
mice. To create mice on the MMTV-Ron background
that are deficient in ERa protein, we then crossed
ERRN mice with transgenic mice expressing Cre recom-
binase under the direction of the whey acidic protein
promoter (WAP-Cre) to obtain WAP-Cre Mice/ERfl/fl/
MMTV-Ron (WPERRN) mice and littermate controls
(ERRN). The ERRN control mice develop mammary
tumors with 100% penetrance and a median time to
palpable tumor of 314 days (Figure 3A). The WAP-Cre
Mice/ERfl/fl/MMTV-Ron (WPERRN) mice also develop
mammary tumors with 100% penetrance; however the
WPERRN mice exhibited a significant increase in tumor
latency (p < 0.05, log-rank test) compared to controls
(Figure 3A). The median tumor latency in this group is
increased by 12.5 days to 326.5 days compared to mam-
mary tumors from ERRN mice.
To verify Cre-mediated deletion of a 680 bp region
of the ERa allele, conventional PCR was performed on
DNA isolated from excised mammary tumors of ERRN
and WPERRN mice. All ERRN mice had the endogen-
ous full length 1280 bp wild-type ERa allele, repre-
sented by lanes 1 and 2 in Figure 3B. Of the 16
mammary tumors analyzed from WPERRN mice, all
had both the wild-type ERa allele (1280 bp band) and
the knockout ERa allele (600 bp band). Four animals
had a wild-type band that was greater than 2-fold
stronger than the knockout band as shown in lane 5
(Figure 3B) suggesting limited ERa deletion in this
tumor. These mice were excluded from all analyses,
including Figure 3A. The remaining 12 tumors had a
greater than 5-fold more intense knockout band com-
pared to the wild-type band and are represented by
lanes 3-4, 6-7 (Figure 3B). To determine the extent of
ERa protein depletion, whole tissue lysates from ERRN
and WPERRN mammary tumors were examined by
Western analyses. ERa protein was reduced approxi-
mately 50% as shown in Figure 3C and quantified in
Figure 2 Tissue array immunohistochemical staining for Ron.
(A) Comparison of Ron staining score in DCIS versus invasive cancer
subtypes (p < 0.01, Mann-Whitney test, n = 250). (B) Comparison of
Ron staining score among T-stage (Tis = carcinoma in situ, T1 =
tumor < 20 mm, T2 = tumor > 20 mm and < 50 mm and T3/4 =
tumor > 50 mm). Tis versus T1, and T2 versus T3/4 did not reach
statistical significance, but all other pairwise comparisons had p-
values < 0.05 by Kruskal-Wallis test followed by Dunn’s multiple
comparisons (n = 250).
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Figure 3D. Given the heterogeneous origin of the
mammary tumor tissue, and the expression pattern of
whey acidic protein, it is not surprising that ERa is
still present, albeit at lower levels. To verify that ERa
was indeed deleted from the tumors of WPERRN
mice, and to document the percentage of ERRN mice
that developed ERa-positive tumors, we performed
immunohistochemistry on tumor sections. Using a
scoring system previously described for determining
ER-positivity [24], we determined that in ERRN mice,
ERa-positive tumors occur approximately 58% of the
time (7/12) (Figure 3E). In contrast, none of the nine
WPERRN mice had ERa-positive tumors (Figure 3F).
Analysis of proliferation and death rates in WPERRN and
ERRN tumors
The increase in latency of WPERRN tumors compared
with ERRN tumors suggests that tumor cell prolifera-
tion and/or apoptosis may be altered. To examine this,
we performed BrDU and TUNEL staining on end-stage
mammary tumors, which was defined as a primary
tumor reaching ~2.5 cm3 in size. Interestingly, BrDU
incorporation was not significantly different in
WPERRN mice versus ERRN mice (Figure 4A), nor
was TUNEL staining (Figure 4B). To more accurately
assess the proliferation and apoptosis rates during
tumor initiation, we harvested mammary glands from
age matched WPERRN and ERRN mice at 220 days of
age and stained for BrDU and TUNEL. This time
point was determined to be optimal for obtaining
mammary glands with hyperplasia, but prior to palp-
able tumor formation. At 220 days old, WPERRN
mammary epithelial cells displayed significantly lower
BrDU incorporation than in ERRN mice (Figure 4C).
Representative images for 220 day old BrDU staining
are shown in Figure 4E and 4F. TUNEL staining at
220 days old was low in these neoplastic regions and
was not different between ERRN and WPERRN ani-
mals (Figure 4D, G and 4H).
Alterations in metastatic burden in WAP-Cre/ERfl/fl/MMTV-
Ron Mice
The liver and lungs were targeted for metastatic foci
examination and quantification. Previously, we reported
that MMTV-Ron transgenic mice develop metastases to
these two organs [13]. The lungs and livers were excised
and fixed in formalin at the time of sacrifice. The lungs
of ERRN and WPERRN mice both contained metastases
that were histologically similar (Figure 5A). To quantify
the overall metastatic burden, we first determined the
metastatic rate to the lungs using a binary system (+ or
-). The proportion of mice with metastases between
ERRN and WPERRN mice was not statistically different
(89% and 96% respectively; Z value = 0.39) (Figure 5B).
However, histological examination of the number of
metastatic foci in a single lobe revealed that the
WPERRN mice carried a higher metastatic burden in
the lungs than the ERRN mice (Figure 5C). Immunohis-
tochemical staining for cytokeratin 18 verified the origin
Figure 3 Tumor characteristics of ERRN and WPERRN mice. (A)
Tumor latency plotted on a Kaplan-Meier curve showing
percentage of ERRN (n = 15) versus WPERRN (n = 12) mice that
were tumor free versus time (p < 0.05, log-rank test). (B) DNA bands
resulting from conventional PCR on genomic DNA isolated from
tumor tissue of ERRN and WPERRN mice. Cre-mediated
recombination results in ERa knockout tumor tissue, shown by the
presence of a 0.6 kb PCR product; while the wild-type ERa product
is 1.28 kb. (C) Western blot of ERa on tumor tissue lysates from
ERRN and WPERRN mice with (D) quantification. (E, F)
Immunohistochemical staining for ERa on mammary tumor sections
from ERRN and WPERRN mice. Numbers represent the proportion of
animals in each genotype that developed ER-positive tumors. Scale
bar = 50 μm.
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of the metastases as from the breast (data not shown).
Next we examined the livers of ERRN and WPERRN
mice. As with the lungs, both genotypes had liver metas-
tases that were histologically indistinguishable from each
other (Figure 5D). Again using a binary scoring system
for the presence of liver metastases, we determined that
56% of ERRN mice and 96% of WPERRN mice had
metastatic liver foci (P < 0.01 Z value = 2.98) (Figure
5E). We confirmed the origin of the foci by immunos-
taining for cytokeratin 5, which was determined to be
present in the MMTV-Ron mammary tumors and not
in hepatocytes (data not shown). Next, we sought to
determine the extent of ER positivity in the metastases.
The metastases in all genotypes and both tissues stained
Figure 4 Analysis of proliferation and cell death in ERRN and WPERRN tumors. BrDU immunohistochemical staining was performed on
end-stage tumors (> 2 cm3) (A) and mice with neoplasias at 220 days old (C). Bars represent the average number of positive cells per field of
view (0.25 mm2). Pictures (E) and (F) correspond to ERRN (n = 7) and WPERRN (n = 7) representative examples, respectively. TUNEL staining was
performed on end-stage tumors (B) and 220 day old mice (D). Bars represent the average number of positive cells per field of view (0.25 mm2).
Pictures (G) and (H) correspond to ERRN (n = 7) and WPERRN (n = 7) representative examples, respectively. Scale bar = 50 μm.
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Figure 5 Metastatic burden analysis on the lungs and livers of ERRN and WPERRN mice. H&E photomicrographs of a lung (A) and liver
(D) metastasis is shown for ERRN and WPERRN genotypes. Proportion of mice having either lung (B) or liver (E) metastases is shown for ERRN
(white bars n = 24) and WPERRN (black bars n = 24) mice (z-test). (C) Bars represent the average number of metastatic foci found per lobe of a
lung in ERRN and WPERRN animals (t-test). (F) Immunohistochemical staining for ER in the metastases of ERRN and WPERRN lung and liver.
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negative for ER (Figure 5F). This reduction in the num-
ber of metastases may be reflective of the proportion of
ER negative tumors in the different genotypes. Overall,
we demonstrate the MMTV-Ron driven tumors that
have deleted ERa have a higher metastatic burden to
the lungs and liver.
ERa deletion in MMTV-Ron tumors is associated with
decreased expression of ER-dependent genes
To explore a potential mechanism by which ERa deletion
leads to increased latency and enhanced metastasis, we
evaluated the expression of ERa-dependent target genes
by real-time PCR and western blotting. Cyclin D1
(CCND1), mothers against decapentaplegic homolog 3
(SMAD3) and cathepsin D (CTSD) are genes known to be
stimulated by ERa activation [25-27]. Tumor tissue repre-
senting WPERRN and ERRN mice was homogenized and
the total RNA isolated. Real-time PCR was performed on
seven independent samples, plated in duplicate. In
WPERRN mice the expression of CCND1, SMAD3 and
CTSD were all decreased compared to ERRN animals by
approximately 60% (P < 0.01, 0.02, 0.005 respectively)
(Figure 6A, B & 6C respectively). Whole protein lysates
from WPERRN and ERRN tumors were also analyzed for
expression of cyclinD1. Expression of cyclinD1 was
decreased in WPERRN tumors, which correlates with the
gene expression studies (Figure 6D). Furthermore, proges-
terone receptor, a well-known protein product of ER sig-
naling was also decreased to a similar extent as cyclinD1
(Figure 6D).
Figure 6 Expression changes of ER-regulated genes. (A, B, C) Bars represent the relative mRNA expression levels between ERRN (n = 7) and
WPERRN (n = 7) tumor lysates, quantified by qPCR. The ER-regulated genes (A) CyclinD1 (CCND1) (B) SMAD3 and (C) cathepsin D (CTSD) were
analyzed (t-test). (D) Protein lysates were also analyzed by Western blotting for expression of cyclin D1 and progesterone receptor.
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Pure ERfl/flRon and ER-/-Ron cells recapitulate tumor
growth phenotypes
Although, WPERRN animals had delayed tumor latency,
the ERa deletion did not display 100% penetrance (see
Figure 3B). Therefore to confirm the tumor growth phe-
notype, we established a cell line derived from an ERfl/
flMMTV-Ron tumor. We subsequently infected the ERfl/
flMMTV-Ron tumor cells with an adenovirus expressing
Cre-recombinase and GFP or GFP alone. GFP-positive
cells were isolated by FACS and cultured to establish
ERfl/flRon cells and ER-/-Ron cells. PCR analysis con-
firmed the Cre-mediated deletion of a 600 bp region of
exon 3 of ERa (Figure 7A). This deletion was still evi-
dent at passage 23, with no contaminating wild-type
ERa allele detected (data not shown); and all subsequent
experiments were performed between passages 5 and 15.
First, the proliferative rates of ERfl/flRon cells and ER-/-
Ron cells were compared by the MTT assay and BrDU
incorporation. Confirming the phenotype of ERRN and
WPERRN mice, the ERfl/flRon cells displayed an
increased proliferative rate compared to ER-/-Ron cells,
by both MTT (Figure 7B) and BrDU incorporation
experiments (Figure 7C). No differences in cell death or
apoptosis were observed between the ERfl/flRon and
ER-/-Ron cells as judged by Annexin V and propidium
iodide (PI) staining (data not shown). Next, to detect
differences in metastatic potential, migration experi-
ments were performed. Again supporting the phenotype
observed in mice, the ER-/-Ron cells migrated more
aggressively across a transwell membrane (Figure 7D).
The ER-/-Ron cells also invaded significantly more on
transwell membranes which were coated with Matrigel®,
a basement membrane protein (data not shown).
Furthermore, when these same cells were injected into
the mammary fat pads of adult athymic nude mice, lar-
ger tumors were observed in ERfl/flRon cell orthotopic
injections compared to ER-/-Ron cells (10 weeks) (Figure
7E &7F). Metastases were not found in the lungs or
livers of either group of nude mice at the time of sacri-
fice; prohibiting analysis of metastatic burden.
Discussion
In this study we have genetically deleted ERa in a rele-
vant model of murine mammary cancer (MMTV-Ron).
We have shown that Ron expression is associated with
early stage ER+ human breast cancers with the highest
levels of Ron observed in carcinomas in situ. Ductal car-
cinomas in situ (DCIS) represent an increasing popula-
tion of new patient diagnoses. Currently, 20-30% of new
cases are classified in this type [28] and evidence exists
that DCIS is a precursor lesion for invasive cancer [28].
Therapeutic options for treating DCIS depend on hor-
mone status and the patient’s wishes. Patients with ER+
DCIS usually undergo lumpectomy and receive
tamoxifen as a neoadjuvant or adjuvant therapy [28].
Since Ron is often overexpressed in these types of
tumors, and Ron has previously been shown to mediate
tamoxifen insensitivity, our data suggest that Ron may
be an important biomarker for predicting chemothera-
peutic resistance.
Previous work has shown that estrogen acts as a carci-
nogen via three independent mechanisms: (1) stimula-
tion of proliferation through receptor signaling, (2)
direct genotoxic effects via cytochrome P450, and (3)
induction of aneuploidy [29]. In addition, the role of
estrogen in stimulating proliferation in both normal and
neoplastic tissue is well documented (30). Proliferation
due to estrogen is dependent on ERa. In this study, we
were able to remove estrogen-ERa mediated prolifera-
tion by genetic manipulation. During tumor develop-
ment, we observed that ERa deficient mammary tumors
have a lower proliferative rate as measured by BrDU
incorporation. Our studies also document an increase in
tumor latency in these mice. Furthermore, cells derived
from these tumors and manipulated to re-create the ER-
replete and ER-knockout conditions recapitulated the
proliferative phenotype observed in these animals. This
confirms that in our MMTV-Ron driven model of carci-
nogenesis, estrogen-ERa signaling plays a proliferative
role that can be attenuated by ERa deletion.
Interestingly, our studies provide important informa-
tion related to the loss of ERa in the context of Ron
overexpression, in that while mammary tumors with this
loss grew slower, the tumors were overall more meta-
static. This data suggest that the context in which ERa
is deleted (or inhibited as in the case of anti-estrogen
therapy akin to clinical studies), Ron may play an
important role in regulating tumor progression and
metastasis. In this case, a suggestion of dually targeting
Ron and ERa may prove advantageous. While further
studies are warranted to understand the mechanisms
associated with the enhanced metastatic phenotype, a
potential mechanism is that in WPERRN tumors com-
pared to controls, the levels of the ER-regulated genes
SMAD3 and cathepsin D are lower. Decreased expres-
sion of SMAD3 has been shown to uncouple TGF-beta
signaling, resulting in a local immunosuppressive envir-
onment [30]. Cathepsin D functions primarily as a lyso-
somal peptidase in the processing of antigen for
presentation. Inhibition or decreased expression of
cathepsin D results in decreased antigen processing and
presentation [31]. In conjunction with ER-dependent
gene changes, Ron activation has been shown to play an
important role in the suppression of innate immunity
[32,33]. Taken altogether, the decreased expression of
SMAD3 and cathepsin D due to ER loss, and concomi-
tant overexpression of Ron may provide an environment
favoring immune system evasion, which may be
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Figure 7 Characterization of ERfl/flRon and ER-/-Ron cells. (A) PCR analysis of genomic DNA confirming the presence of the wild-type ERa
allele (1280 bp) in ERfl/flRon cells and the knockout allele (600 bp) in ER-/-Ron cells. (B) Bars represent the absorbance measured at 570 nm
following MTT assay on ERfl/flRon and ER-/-Ron cells (n = 8). (C) Bars represent the percentage of BrDU positive cells per 10 × field of ERfl/flRon
and ER-/-Ron cells following BrDU incorporation (n = 6 independent experiments with 6-8 fields counted per genotype/experiment). (D) Bars
represent the absorbance measured at 570 nm following a transwell migration assay on ERfl/flRon and ER-/-Ron cells (n = 4 independent
experiments performed in triplicate). (E) Bars represent the mean mass of the tumors established from orthotopic injections of ERfl/flRon and ER-/-
Ron cells (n = 7 mice per cell line) into the fat pads of athymic nude mice a time of sacrifice (10 weeks post injection). All means were
compared by student’s t-test. (F) Representative photographs of tumors established from orthotopic injections of ERfl/flRon and ER-/-Ron cells into
the fat pads of athymic nude mice.
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contributing to the enhanced metastatic phenotype.
Testing this hypothesis, preliminary experiments showed
that F480 staining in primary tumors was not signifi-
cantly different between ERRN and WPERRN genotypes
(data not shown). Further investigation is needed to ver-
ify and expand upon these findings.
The increased metastatic burden found in the
WPERRN mice is interesting on two levels. First, these
mice had neoplastic lesions that were slower to prolifer-
ate than ERRN neoplasias. There has been recent evi-
dence suggesting that slower growing tumors
metastasize at a higher rate [34]. The second level
where the alteration in metastasis is interesting is with
respect to anti-estrogen endocrine therapies. Tamoxifen
and other anti-estrogen therapies ultimately fail due to
acquired resistance. The endocrine therapy selects for
tumor cells that can survive without the proliferative sti-
mulation from estrogen-ERa activation. One observed
consequence of resistance is increased tumor aggressive-
ness [35]. Our studies suggest that similar mechanisms
are occurring in the WPERRN mice, where ERa has
been deleted, rather than pharmacologically antagonized.
In short, this model genetically recapitulates some
aspects of acquired chemotherapeutic resistance due to
ER inhibition, namely less proliferative tumors with an
increased metastatic capacity.
Conclusions
In summary, the data herein demonstrate that Ron is
overexpressed breast cancers with high levels or Ron
observed in early stage ERa-positive breast cancers. Our
studies also show that a conditional loss of ERa in
mammary epithelium of Ron overexpressing mice leads
to the development of breast tumors which exhibit
diminished growth and increased metastases.
Methods
Animal Procedures
MMTV-Ron (FVB/N) mice were crossed to ERafl/fl
(C57/B6) mice to generate ERafl/fl/MMTV-Ron animals,
abbreviated ERRN. Both transgenic strains are indepen-
dently described elsewhere [13,18]. The ERRN mice
were then crossed with transgenic mice carrying an
allele for whey acidic protein promoter driving expres-
sion of Cre recombinase (WAP-Cre) [36,37] to create
WAP-Cre/ERafl/fl/MMTV-Ron animals, abbreviated
WPERRN, plus littermate controls. Primers used for
genotyping and recombination efficiency were described
previously [13,18]. For tumor production and to ensure
WAP-Cre expression, all females used in experiments
were housed with males throughout the duration of the
experiment to promote parity. All females were multi-
parous, and no differences in parity were observed
between WPERRN and ERRN animals. Mice were
palpated bi-weekly for determination of tumor latency.
Tumors reaching 20% of body mass were considered
end-stage, and animals were sacrificed. Athymic nude
mice were purchased from NCI-Frederick (Frederick,
MD). For orthotopic injections, 2 × 106 cells were sus-
pended in a 1:1 mixture of DMEM:F12 and Matrigel®
(BD Biosciences) and injected into the fat pad of
anesthetized mice. All procedures were approved by the
University of Cincinnati Institutional Animal Care and
Use Committee.
Reagents
Primers used for genotyping mice were as follows:
MMTV-Ron forward 5’TGG GTG GTG AGG TCT
GCC AAC ATG A3’, reverse 5’CCG TCT TCG GGA
GTT AAA GAT CAG GG3’; ERafl/fl forward 5’TGG
GTT GCC CGA TAA CAA TAA C3’, reverse 5’AAG
AGA TGT AGG GCG GGA AAA G3’; WAP-Cre for-
ward 5’CAT CAC TCG TTG CAT CGA CC3’, reverse
5’TAG AGC TGT GCC AGC CTC TTC3’. The ERafl/fl
primers were also used for determining the deletion
event in Cre-positive tumors and Cre-infected cells.
Adenovirus expressing Cre and GFP or GFP described
previously [22]. MTT reagent (Sigma, St. Louis, MO)
was dissolved in PBS, added to the cells for 3 hours and
the intensity of the resulting solution quantified on
spectrophotometer at 570 nm.
Immunoblotting and Immunohistochemistry
For immunoblotting, whole cell lysates were prepared in
radioimmunoprecipitation assay (RIPA) buffer (20 mM
Tris, 150 mM sodium chloride, 2 mM EDTA, 0.1%
SDS, 1% Triton-X 100, 0.5% sodium deoxycholate, 10%
glycerol) supplemented with Complete protease inhibi-
tor tablets (Roche, Palo Alto, CA) and HALT phospha-
tase inhibitors (Pierce, Rockford, IL). Protein
concentrations were determined by Micro BCA Protein
Assays (Pierce, Rockford, IL). Lysates were then boiled
for 10 minutes in buffer containing beta-mercaptoetha-
nol and separated by SDS-PAGE. Immunoblotting was
carried out according to standard procedures on PVDF
membrane, with enhanced chemiluminescence detection
(GE Healthcare, Piscataway, NJ). Antibodies used were
the following: anti-mouse ERa (clone MC-20; Santa
Cruz, Santa Cruz, CA), anti-human Ron b (clone C-20
Santa Cruz, Santa Cruz, CA), anti-mouse progesterone
receptor (clone C-19, Santa Cruz), and anti-mouse
cyclinD1 (clone 72-13G, Santa Cruz). Densitometry was
performed on NIH ImageJ analysis software. For immu-
nohistochemistry, tissues were fixed in neutral-buffered
formalin, embedded in paraffin, and sectioned. Rehy-
drated sections were subjected to antigen retrieval and
incubated in primary antibody overnight at 4°C. Sec-
tions were then, washed, incubated in biotin-conjugated
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goat secondary antibody for 1 hr at room temperature,
and visualized with ABC-DAB kit (Vector Labs, Burlin-
game, CA).
Quantitative real-time polymerase chain reaction analysis
Frozen tumor tissue from ERRN and WPERRN mice
was homogenized and lysed in Tri-reagent (MRC, Cin-
cinnati, OH). RNAs was isolated from Tri-reagent
reagent solutions by chloroform-isopropanol extraction.
DNA was prepared from isolated RNAs using High
Capacity cDNA Reverse Transcriptase kit (Applied Bio-
systems, Foster City, CA), per manufacturer instructions.
The sequences for primers are as follows: for CCND1
(5’CTC CTC TTC GCA CTT CTG CTC3’, and 5’GCG
TAC CCT GAC ACC AAT CTC3’), for SMAD3 (5’
CCT TCT GGT GCT CCA TCT CC3’, and 5’ACA CCT
CTC CCA ATG TGT CG3’), for CTSD (5’CCT TTG
ACA TCC ACT ACG GC3’ and 5’AAG ATG CCA
TCA AAC TTG GC3’). Expression of these genes was
normalized to expression of b-glucuronidase (GUS,
5’TTG AGA ACT GGT ATA AGA CGC ATC AG3’,
5’TCT GGT ACT CCT CAC TGA ACA TGC3’). Quan-
titative real-time PCR was performed using SYBR-green
in 96-well plates read with 7900 HT Fast Real-Time
PCR/Sequence Detection Systems (Applied Biosystems,
Foster City, CA).
Cell Based Assays
For migration assays, 1 × 105 ERfl/flRon or ER-/-Ron
cells were plated in the top chamber of 0.8 μm trans-
wells (Corning Costar Corporation, Cambridge, MA)
and were allowed to migrate towards 5% FBS DMEM-
F12 media for 24 hours. The number of live cells on
the bottom of the transwell was measured using an
MTT assay according to the manufacturer’s instruc-
tions (Sigma-Aldrich, St. Louis, MO) with absorbance
read at 570 nm. Invasion assays were performed simi-
lar to the migration assays except that the transwell
inserts were coated with Matrigel™ (BD Biosciences,
Billerica, MA) and invasion was assessed at 48 hrs. For
cell death assays, cells were plated at equal densities
followed by serum starvation for 48 hours. The cells,
including the floating/dead cells, were collected and
stained with AnnexinV and propidium iodide (BD
Pharmingen, San Diego, CA) and analyzed by flow
cytometry according to the manufacturer’s instructions.
Cell proliferation assays were accomplished by plating
cells on glass cover slips. The cells were labeled for 4
hours with 5-bromo-2’-deoxyuridine (BrDU) and
stained according to the manufacturer’s instructions
(RPN20, GE Healthcare Life Sciences, Piscataway, NJ).
The number of BrDU positive cells and the total num-
ber of cells in a 10 × field were counted and
represented as the percentage of BrDU positive cells
per group.
Tissue Microarray
The tissue arrays were purchased from the National
Cancer Institute’s Cooperative Breast Cancer Tissue
Resource (CBCTR 2nd Generation Progression Tissue
Microarray). Each array was purchased in duplicate, one
serving as an isotype control for the immunohistochem-
istry that was performed as described above. Samples
were scored as previously described for intensity on a 0-
3 scale and for percent positivity (0-100%) [22,23]. The
two parameters were multiplied to give an overall score
(0-300). Blinded scoring was performed by two indepen-
dent scorers, and the average score was calculated and
used for each sample.
Statistical Analysis
The statistical test for each experiment is listed in the
corresponding figure legend. A p-value of < 0.05 is con-
sidered significant. All data were analyzed using Graph-
pad Prism software (LaJolla, CA).
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